Denison Pharmaceuticals, LLC

FDA inspection history in Lincoln, Rhode Island, 2016 to 2024

4
Form 483s
1
Warning letter

Every document, by year

  • Form 483
  • Warning letter

2016: one Form 483; 2017: one Form 483; 2023: one warning letter and one Form 483; 2024: one Form 483.

The story so far

Built from the dates and citations on the documents themselves.

  1. 2016–17Two Form 483s, at Lincoln, Rhode Island.
  2. 2023–24Two Form 483s and one warning letter, at Lincoln, Rhode Island.
  3. 2024The longest 483 on file: 11 observations over 15 pages at Lincoln, Rhode Island.

Cited most

Across all Denison Pharmaceuticals observations on file

The complete Denison Pharmaceuticals file.

All 5 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.

$421$495

15% off buying them one by one

Sites

Documents

5 on file, newest first
DateDocumentPrice
2024-07-29483 Form 483$99
2023-07-26Warning letter Warning letter$99
2023-02-09483 Form 483$99
2017-10-25483 Form 483$99
2016-04-05483 Form 483$99

FEI number 1210580 · most recent document Jul 29, 2024

About Denison Pharmaceuticals, LLC

How many FDA Form 483s has Denison Pharmaceuticals, LLC received?

FDA Intel has 4 Form 483s on file for Denison Pharmaceuticals, LLC; the most recent is dated Jul 29, 2024.

When was Denison Pharmaceuticals, LLC last inspected by FDA?

The most recent FDA inspection document on file for Denison Pharmaceuticals, LLC is a Form 483 dated Jul 29, 2024, for the site in Lincoln, Rhode Island.

What did FDA cite at Denison Pharmaceuticals, LLC?

The regulations cited most in the observations on file for Denison Pharmaceuticals, LLC are 21 CFR 211.192 (Production record review), 4 times; 21 CFR 211.22(d) (Responsibilities of quality control unit), 4 times; 21 CFR 211.100(a) (Written procedures; deviations), 2 times.

Has Denison Pharmaceuticals, LLC received an FDA warning letter?

Yes. FDA Intel has 1 FDA warning letter on file for Denison Pharmaceuticals, LLC; the most recent is dated Jul 26, 2023.